Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

Nasdaq debutante Septerna swells its IPO to $331m

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.

AbbVie taps Sosei Heptares GPCR expertise with $1.2bn+ allia...

Sosei Heptares has signed up a string of big pharma collaborators over the last few years, and one of them – AbbVie – has just expanded its partnership with a new to deal to apply the biote

UK biotech OMass raises £27.5m for GPCR drug discovery

Sosei Heptares bags another big partnership, this time with ...